LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer
LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer
LIXTE Biotechnology宣佈與羅氏和荷蘭癌症研究所合作，在MSI低轉移結直腸癌中進行LB-100增強免疫識別結直腸癌細胞的臨床試驗。
LIXTE Biotechnology Announces Collaboration With Roche And Netherlands Cancer Institute For Clinical Trial On LB-100's Effectiveness In Enhancing Immune Recognition Of Colon Cancer Cells In MSI Low Metastatic Colon Cancer
LIXTE Biotechnology宣佈與羅氏和荷蘭癌症研究所合作，在MSI低轉移結直腸癌中進行LB-100增強免疫識別結直腸癌細胞的臨床試驗。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。